This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MOUNTAIN VIEW, Calif., Oct. 3, 2012 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced several Qsymia scientific presentations at the 48th Annual Meeting of European Association for the Study of Diabetes (EASD) currently underway in Messe Süd, Berlin, Germany.
On Wednesday, October 3, 2012, the following posters will be presented:
Poster Number 695 – Arne Astrup, MD, DMSc (Presented by Hermann Toplak, MD)
Jean-Michel Oppert, MS, PhD; Craig A. Peterson, MS
Weight Loss and Improvements in Cardiometabolic Outcomes With Extended-Release Phentermine/Topiramate Treatment in Overweight/Obese Subjects With Type 2 Diabetes
Abstract Number A-12-290-EASD
Poster Number 696 – Stephan Rössner, MD, PhD
Arya M. Sharma, MD, PhD; Barbara Troupin, MD, MBA; Raj Padwal, MD
Effects of Extended-Release Phentermine/Topiramate on Weight Loss and Blood Pressure in Obese Subjects With Type 2 Diabetes Mellitus
Abstract Number A-12-1079-EASD
Poster Number 697 – Jens Jordan, MD
Arne Astrup, MD, DMSc; Wesley W. Day, PhD
Effects of Phentermine and Extended-Release Topiramate Alone and in Combination on Cardiovascular Risk Factors
Abstract Number A-12-993-EASD
Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m
2 or greater (obese) or 27 kg/m
2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
Important Safety Information
Qsymia (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.
Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.